Johnson & Johnson received FDA approval for Inlexzo (formerly TAR-200), a drug-device system releasing gemcitabine into the bladder to treat Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC). Clinical trials showed an 82% complete response rate; the therapy may help patients avoid cystectomy. J&J projects strong commercial success, highlighting the convenience of its device-based treatment approach.